In March, the FDA approved Aerie Pharmaceuticals’ netarsudil and latanoprost compound for the treatment of glaucoma and ocular hypertension. The news was the most-read glaucoma article on Healio/OSN in 2019.
Here are the top five glaucoma stories of the past year:
FDA approves Rocklatan for open-angle glaucoma, ocular hypertension
A fixed-dose combination of netarsudil and latanoprost, Rocklatan — previously known as Roclatan — is designed to target the trabecular meshwork, which is considered the main cause of elevated IOP. Read more.
FDA accepts application for
Uncategorized